Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration

Executive Summary

The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.

You may also be interested in...



Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic

Company’s technology harnesses E3 ligases to either degrade dysregulated proteins or inhibit a specific ligase to increase substrate protein levels for therapeutic benefit.

Bayer Pays Arvinas $50m To Form Protein Degrader R&D Pact

The partnership gives the German major another potential source of drugs to treat cardiovascular, oncological and gynecological diseases.

Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group

Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC099888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel